Chief of the New Mexico Department of Health's (NMDOH) Environmental Health Epidemiology Bureau
Key decision makers in the same organization
Organization Signals
Public Activity & Signals
Board meetings, strategic plans, and buyer signals from Jeffrey Lara’s organization
Aug 19, 2026·BoardMeeting
Board
Dosage, Administration and Clinical Practice Committee Committee Meeting
The committee discussed and voted to move forward with recommendations regarding the integration of psilocybin treatment sessions. Topics included the purpose and scope of integration sessions, circle of care methods such as individual and group sessions, patient-centered integration planning, and the establishment of an integration timeline. Additionally, guidelines for clinical documentation, including recording the patient's dosing experience, mental status, and adverse event screening, were reviewed and adopted.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
Medical Psilocybin Program Advisory Board Meeting Minutes
The meeting included program updates regarding the upcoming acceptance of applications for producers and laboratories, the absence of application fees, and ongoing rule development for training and education, with further rulemaking anticipated throughout the year. The Department of Health emphasized that rulemaking is an iterative process and provided clarification regarding medical certification requirements for psilocybin care. Additionally, the board discussed priority items for future meetings, specifically the need for guidelines and best practices from the Equity, Access, and Cultural Considerations Committee, as well as the utilization of the Treatment Equity Fund.
Aug 7, 2026·BoardMeeting
Board
Research and Continuous Improvement Committee Committee Meeting
The meeting featured a presentation on data security, privacy, and governance within the context of the Medical Psilocybin Program. Key discussion topics included establishing a 'trust by design' framework, the ethics of patient data usage, and progressive disclosure to enable research without compromising individual privacy. The committee also reviewed its purpose and responsibilities and unanimously voted to advance a proposed harm reduction and quality improvement framework to the Advisory Board and the Department of Health.
Jul 21, 2026·BoardMeeting
Board
Equity Access and Cultural Considerations Committee Committee Meeting
The committee meeting focused on establishing eligibility criteria for the Treatment Equity Fund, specifically voting to set the threshold at 200% of the Federal Poverty Level. Discussions included considerations for multiple medicine sessions, geographic and condition-based allocation of funds, and potential coordination with insurance and Medicaid coverage. Participants provided public comments on financial barriers to treatment and the need for inclusive, accessible therapy models.
Extracted from official board minutes, strategic plans, and video transcripts.
